The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

It is the first approval for Beyfortus (nirsevimab) by any regulatory authority. AZ's Synagis (palivizumab) is currently the only approved drug in Europe to provide passive prophylaxis against RSV ...

Dr. Patrick Hemmons travelled to Seattle to get an RSV shot for his daughter. He says he hopes to see nirsevimab become more easily accessible across the country.

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

Sanofi and partner AstraZeneca’s AZN RSV antibody Beyfortus (nirsevimab) recorded sales of €841 million in the fourth quarter, up 107% year over year, driven by higher sales in the United ...

vaccine Beyfortus (nirsevimab), developed as part of a partnership with AstraZeneca. Whilst revealing its Q4 2024 results, Sanofi said it is planning to execute a $5.12bn share buyback programme ...

as well as AstraZeneca and partner Sanofi’s SNY respiratory syncytial virus (“RSV”) antibody Beyfortus (nirsevimab). AstraZeneca records 50% share of gross profits on sales of Beyfortus in ...

The pioneering beyfortus provides a solution to decrease RSV cases. It bolsters passive immunity through a single-dose monoclonal antibody, nirsevimab, which targets and neutralizes the ...

Management expects Beyfortus penetration to grow further with geographic expansion. Gross margin and R&D expenses are also anticipated to increase slightly in 2025, supported by preparations for u ...